Screener
Royalty Pharma RPRX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 59.6%-20.2pp | 65.1%-18.9pp | 65.6%+8.5pp | 65.2%-2.9pp | 79.8%+36.9pp | |
| Net margin | 32.1%-12.3pp | 34%-14.3pp | 32.5%-5.4pp | 32.7%-17.9pp | 44.4%+14.3pp | |
| Returns | ||||||
| Return on equity | 8.5%-2.2pp | 8.4%-2.7pp | 7.7%-0.7pp | 7.7%-3.8pp | 10.6%+3.8pp | |
| Return on invested capital | 8.7%-2.7pp | 9.2%-2.9pp | 8.9%+1.0pp | 8.9%-0.9pp | 11.3%+5.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.8×+1.5× | 2.7×+1.1× | 2.4×+1.0× | 3.5×+1.9× | 1.3×-8.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.9×+0.1× | 0.9×+0.1× | 0.9×+0.2× | 0.9×+0.2× | 0.8×+0.1× | |
| Per Share | ||||||
| Book value per share | $17.57+4.1% | $17.85+5.5% | $17.21-1.1% | $17.19-0.7% | $16.88+3.3% | |
| Valuation | ||||||
| Market capitalization | $25.6B+63.7% | $20.55B+52.4% | $16.51B+45.7% | $15.25B+20.3% | $15.23B+27.7% | |
| Price / earnings | 31.4×+16.1× | 24.8×+12.4× | 21.3×+8.1× | 19.9×+8.8× | 14.9×-2.8× | |
| Price / sales | 10.1×+3.3× | 8.4×+2.5× | 6.9×+1.9× | 6.5×+0.9× | 6.6×+1.3× | |
| Price / book | 2.6×+1.0× | 2.1×+0.7× | 1.7×+0.6× | 1.6×+0.3× | 1.6×+0.4× |
FAQ
- Where do Royalty Pharma's ratios come from?
- Every ratio is computed from Royalty Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
